Brief: IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate
24/03/2025 12:46
March 24 (Reuters) - Icecure Medical Ltd ICCM.O: ICECURE'S ICESECRET KIDNEY CANCER CRYOABLATION STUDY INTERIM RESULTS PRESENTED AT EUROPEAN ASSOCIATION OF UROLOGY CONFERENCE IN SPAIN: 88.7% RECURRENCE-FREE RATE Source text: ID:nPn8S4dnca Further company coverage: ICCM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Icecure Medical
See all newsIcecure Medical Ltd reports results for the quarter ended June 30 - Earnings Summary
Israel's IceCure Medical H1 revenue rises on higher system, probe sales
Brief: Icecure Sio Petitions Nccn To Include Cryoablation In Breast Cancer Treatment Guidelines, Citing Icecure's FDA Clearance Of Prosense®
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:45 AM